Home Microbiology Reverse Transcriptase inhibitor - DNA/RNA Synthesis inhibitor - HIV inhibitor 3'-Fluoro-3'-deoxythymidine (Alovudine)

research use only

3'-Fluoro-3'-deoxythymidine (Alovudine) Reverse Transcriptase inhibitor

Cat.No.S6848

3'-Fluoro-3'-deoxythymidine (Alovudine, CL 184824, FddThd, FLT, MIV-310) is a potent inhibitor of polymerase γ and reverse transcriptase that can be used in the treatment of HIV infection. It is also a marker of DNA synthesis that can be used as an early response biomarker in the chemotherapy of pancreatic cancer.
3'-Fluoro-3'-deoxythymidine (Alovudine) Reverse Transcriptase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 244.22

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S684801 DMSO]49 mg/mL]false]Ethanol]40 mg/mL]false]Water]20 mg/mL]false Purity: 99.9%
99.9

Chemical Information, Storage & Stability

Molecular Weight 244.22 Formula

C10H13FN2O4

 Storage (From the date of receipt) 3 years -20°C(in the dark) powder
CAS No. 25526-93-6 -- Storage of Stock Solutions

Synonyms CL 184824, FddThd, FLT, MIV-310 Smiles CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)F

Solubility

In vitro
Batch:

DMSO : 49 mg/mL (200.63 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 40 mg/mL

Water : 20 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
polymerase γ [3]
Reverse transcriptase [2]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05947344 Recruiting
AML Adult
Zhejiang ACEA Pharmaceutical Co. Ltd.
 December 8 2023 Phase 1
NCT05232994 Not yet recruiting
Preeclampsia Severe|Preeclampsia Second Trimester|Preterm Birth Complication
Christiana Care Health Services
 March 1 2023 Phase 1
NCT05697510 Recruiting
Acute Myeloid Leukemia (AML)
Nantes University Hospital
 March 16 2023 Phase 1
NCT03633955 Recruiting
Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Ambiguous Lineage Leukemia or Lymphoma|Myeloma
University of Oklahoma|Emory University
 January 19 2023 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map